We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
In the latest tussle over lucrative patents covering the revolutionary gene-editing technology CRISPR-Cas9, an appeals judge for the U.S. Court of Appeals for the Federal Circuit said she would likely side with the Broad Institute. Read More
In what Regeneron CEO Len Schleifer called a “paradigm-shifting agreement,” Sanofi and Regeneron sealed a deal with the pharmacy benefit manager Express Scripts cutting the price of their cholesterol drug Praulent (alirocumab) by up to $10,000 a year in exchange for easier access for Express Scripts patients. Read More
The medication-assisted treatments will be compared to a tentative list of medications commonly used in MAT, such as methadone, Vivitrol and Suboxone. Read More
A Massachusetts judge ruled that Biogen must face a False Claims Act lawsuit brought by former employees alleging the company paid healthcare providers kickbacks to prescribe Biogen’s multiple sclerosis products, including Avonex, Tecfidera and Tysabri. Read More
In a move applauded by domestic drug groups, the U.S. Trade Representative added Canada to its priority watch list of countries with lax intellectual property protections or market access barriers for drugs. Read More
Citing concerns among stakeholders including the FDA, the U.S. Pharmacopeia decided not to move forward with proposed revisions to its nomenclature for biologics. Read More